Stephanie Ailey Named DM Clinical Research Vice President of Business Development

DM Clinical Research has hired industry veteran Stephanie Ailey as Vice President of Business Development, bringing more than 20 years of program management and healthcare experience to the national clinical trial site network.

“Stephanie has a great track record building strategic relationships that help advance medical research,” said Mohammad Millwala, CEO & Founder of DM Clinical Research. “Our site network has been growing rapidly over the last three years and Stephanie will be an important part of our success going forward. DM Clinical Research expects to launch several new sites before the end of the year and Stephanie’s expertise will be vital to ensuring success as we enter new markets.”

Stephanie Ailey previously served as Vice President of Business Development with both Velocity Clinical Research and Meridian Clinical Research. She also served as Meridian’s Senior Director of Business Development, Director of Business Development, and Director of Operations.

“I love research and had the unique experience of working at the study site that enrolled the first patient globally to participate in a Phase 3 COVID-19 trial,” said Ailey. “I was attracted to DM Clinical Research because of Mohammad and his vision for the company. The commitment Mohammad has shown to not only diversity in clinical trials, but diversity among the staff and primary investigators is inspirational.”

While many study sites and clinical research sponsors continue to struggle to ensure diversity, 48.5% of all participants in DM Clinical Research studies in 2022 identified as diverse. In 2022, the company reported minority enrollment of 50.41% in vaccine studies. DM Clinical Research’s leadership team and employees are also extremely diverse with roughly 75 percent of the company’s more than 600 employees identifying as diverse.

Originally from Oklahoma, Ailey now resides in Savannah, Georgia. Earlier in her career, she served as a Program Manager with the University of Oklahoma and a Child Welfare Specialist with the Oklahoma Department of Human Services. Ailey received a Citation of Appreciation from the Oklahoma State Legislature in recognition of her volunteer work. She earned a Bachelor’s in Communication from Southwestern Adventist University.

Hot this week

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump